Novartis AGNovartis AG - ESG Rating & Company Profile powered by AI

Industry Group:Pharmaceuticals

The ESG score includes seventeen UN SDGs including: 'Clean Water & Sanitation', 'Industry, Innovation & Infrastructure' and 'Life below Water'. The report of Novartis AG leverages intelligence from across the web and also from available documents by Novartis AG. This dashboard contains a Q&A section on Novartis AG.

Novartis AG in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 9.2; made up of an environmental score of 8.0, social score of 6.9 and governance score of 8.0.

SDG Transparency Score for Novartis AG 
Low
0 - 3
Medium
4 - 6

9.2

High Impact
7 - 10
Last Score Update: 2023-07-01
What drives the score for Novartis AG 
8.0

Environmental

6.9

Social

8.0

Governance

Detailed ESG Breakdown
SEVVA Platform offers unique drill down to the underlying sources powering the ratings. Break down your ESG analysis by 17 UN SDGs and 8 additional governance factors.

Peer Group Comparison

RankCompanySDG Transparency Score Performance
1Novartis AG
9.2
High
2Daiichi Sankyo Co Ltd
8.9
High
3Illumina Inc
8.8
High
.........
2749Xynomic Pharmaceuticals Holdings Inc
0.0
Low
2749Zyden Gentec Ltd
0.0
Low
.........
View the full peer group of 3273 companies on the SEVVA platformSign up for free
Peer Companies Benchmark
SEVVA Platform benchmarks each company against a peer group. View the full score distribution for peers by logging into SEVVA

Frequently Asked Questions

Does Novartis AG have an accelerator or VC vehicle to help deliver innovation?

LockedSign up for free to unlock

Does Novartis AG disclose current and historical energy intensity?

LockedSign up for free to unlock

Does Novartis AG report the average age of the workforce?

LockedSign up for free to unlock

Does Novartis AG reference operational or capital allocation in relation to climate change?

LockedSign up for free to unlock

Does Novartis AG disclose its ethnicity pay gap?

LockedSign up for free to unlock

Does Novartis AG disclose cybersecurity risks?

LockedSign up for free to unlock

Does Novartis AG offer flexible work?

LockedSign up for free to unlock

Does Novartis AG have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?

LockedSign up for free to unlock

Does Novartis AG disclose the number of employees in R&D functions?

LockedSign up for free to unlock

Does Novartis AG conduct supply chain audits?

LockedSign up for free to unlock

Does Novartis AG disclose incidents of non-compliance in relation to the health and safety impacts of products and services?

LockedSign up for free to unlock

Does Novartis AG conduct 360 degree staff reviews?

LockedSign up for free to unlock

Does Novartis AG disclose the individual responsible for D&I?

LockedSign up for free to unlock

Does Novartis AG disclose current and historical air emissions?

LockedSign up for free to unlock

Is executive remuneration linked to climate performance?

LockedSign up for free to unlock

Does the Board describe its role in the oversight of climate-related risks and opportunities?

LockedSign up for free to unlock

Does Novartis AG disclose current and / or historical scope 2 emissions?

LockedSign up for free to unlock

Does Novartis AG disclose water use targets?

LockedSign up for free to unlock

Does Novartis AG have careers partnerships with academic institutions?

LockedSign up for free to unlock

Did Novartis AG have a product recall in the last two years?

LockedSign up for free to unlock

Does Novartis AG disclose incidents of discrimination?

LockedSign up for free to unlock

Does Novartis AG allow for Work Councils/Collective Agreements to be formed?

LockedSign up for free to unlock

Has Novartis AG issued a profit warning in the past 24 months?

LockedSign up for free to unlock

Does Novartis AG disclose parental leave metrics?

LockedSign up for free to unlock

Does Novartis AG disclose climate scenario or pathway analysis?

LockedSign up for free to unlock

Does Novartis AG disclose current and / or historical scope 1 emissions?

LockedSign up for free to unlock

Are Operating Expesnses linked to emissions reduction?

LockedSign up for free to unlock

Does Novartis AG disclose the pay ratio of women to men?

LockedSign up for free to unlock

Does Novartis AG support suppliers with sustainability related research and development?

LockedSign up for free to unlock

Does Novartis AG disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?

LockedSign up for free to unlock

Does Novartis AG reflect climate-related risks in its financial statements?

LockedSign up for free to unlock

Is Novartis AG involved in embryonic stem cell research?

LockedSign up for free to unlock

Does Novartis AG disclose GHG and Air Emissions intensity?

LockedSign up for free to unlock

Does Novartis AG disclose its waste policy?

LockedSign up for free to unlock

Does Novartis AG report according to TCFD requirements?

LockedSign up for free to unlock

Does Novartis AG disclose its policies for bribery, corruption, whistle-blower, conflict of interest?

LockedSign up for free to unlock

Does Novartis AG disclose energy use targets?

LockedSign up for free to unlock

Does Novartis AG disclose its Renewable Energy targets?

Only SubscribersSubscription required

Are emissions metrics verified by STBi?

Only SubscribersSubscription required

Does Novartis AG have a policy relating to cyber security?

LockedSign up for free to unlock

Have a different question?

Potential Risks for Novartis AG
These potential risks are based on the size, segment and geographies of the company.

Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatology, respiratory, cardiovascular, renal, and metabolism medicine products. The Sandoz segment develops, manufactures, and markets finished dosage form medicines; active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties; and retail generics and anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.

Sorry!

Failed to process!